Synergistic anticancer effect of acteoside and temozolomide-based glioblastoma chemotherapy

Hwang, Tae-Yeon; Kim, Dong Hun; Kim, Da Bi; Jang, Tae Won; Kim, Gun‐Hwa; Moon, Minho; Yoon, Kyung Ah; Choi, Dae Eun; Park, Jae Ho; Kim, Jwa‐Jin

doi:10.3892/ijmm.2019.4061

Cited by 11 publications

(13 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ACT combined with temozolomide could synergistically enhance the antitumor effect in glioblastoma chemotherapy by reducing cell viability and inhibiting cell migration [27]. However, in other studies, ACT could improve the cell viability of human neuroblastoma SH-SY5Y cells [28, 29].…”

Section: Discussionmentioning

confidence: 99%

Acteoside inhibits inflammatory response via JAK/STAT signaling pathway in osteoarthritic rats

Qiao

Tang

et al. 2019

BMC Complement Altern Med

View full text Add to dashboard Cite

Background: Osteoarthritis (OA) is a common degenerative disease of synovial joints caused by inflammation. Acteoside (ACT), a major component and lipase inhibitor from the Chinese tea Ligustrum purpurascens kudingcha, has been reported to regulate the inflammation and immune response. The study aims to investigate the effects of ACT on inflammatory responses and joint protection in OA rats. Methods: Cell proliferation was examined by MTT and colony formation assay. Apoptosis was analyzed using flow cytometry with Annexin V/PI staining. ELISA was employed to examine the concentration of inflammatory cytokines. OA rat model was established by surgery stimulation. Results: ACT treatment significantly inhibited the upregulation of inflammatory cytokines induced by IL-1β in primary chondrocytes, including IL-6, IL-12, TNF-α and IFN-γ. ACT stimulation also enhanced the cell proliferation, while inhibited cell apoptosis in IL-1β-treated chondrocytes. Consistently, ACT treatment led to downregulation of cleaved-caspase-3 and apoptosis regulator Bax, and upregulation of Bcl-2. Furthermore, ACT treatment inhibited IL-1β-induced activation of JAK/STAT pathway. The results were confirmed in surgery-induced OA rat model. Moreover, ACT treatment significantly inhibited synovial inflammation and articular chondrocyte apoptosis in OA rats. Conclusion: Our findings indicate that ACT has the potential therapeutic effect on OA through inhibiting the inflammatory responses via inactivating JAK/STAT signaling pathway.

show abstract

Section: Discussionmentioning

confidence: 99%

Acteoside inhibits inflammatory response via JAK/STAT signaling pathway in osteoarthritic rats

Qiao

Tang

et al. 2019

BMC Complement Altern Med

View full text Add to dashboard Cite

show abstract

“…In 2018, Chinese researchers studied the anticancer activities of VERB by targeting protein tyrosine phosphatase (SHP-1) and STAT3. The result showed lower activity VERB when administered together with si-SHP-1 (siRNA + SHP-1) and higher cell migration and invasion in comparison to that shown in the VERB-treated mice [37]. Moreover, the survival rate in the mice group treated with combination of temozolomide (TMZ) and VERB was less than that in the groups treated with VERB or TMZ alone with higher apoptosis.…”

Section: Brain Cancermentioning

confidence: 89%

Verbascoside—A Review of Its Antitumor Activities

Khalaf¹,

Jasim²,

Ibrahim³

2021

View full text Add to dashboard Cite

Cancer is a set of diseases including abnormal growth of cells that can spread to another tissue. Verbascoside (or acteoside) is a naturally occurring, water-soluble secondary metabolite with significant biological properties, which is distributed widely in plant kingdom. Verbascoside is pharmacologically active compounds with many recent evidences that support its biological activities and safety. This review focuses on the recent studies that concerned with the antitumor activities of verbascoside alone and as a synergistic agent as well as nanoproduct. It also shows the latest advances in its antitumor effects, cytotoxic selectivity and its efficiencies in treating cancer, in vitro and/or vivo.

show abstract

“…Mounting evidence has shown the antitumor effects of acteoside in various tumor cells such as B16 melanoma cells, glioblastoma cells, colorectal cancer cells, oral squamous cell carcinoma cells, prostate cancer cells and human breast adenocarcinoma cells [ 11 – 13 , 23 – 25 ] or in animals bearing tumors [ 12 ]. Despite that, few studies have focused on the effects of acteoside on HCC in vitro or in vivo except one study using diethylnitrosamine as the carcinogen to induce hepatocarcinogenesis in rats and revealing the chemoprevention by acteoside [ 26 ].…”

Section: Discussionmentioning

confidence: 99%

Acteoside as a potential therapeutic option for primary hepatocellular carcinoma: a preclinical study

Wang

Liu

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

Background Hepatocellular carcinoma (HCC) is a common malignant tumor with characteristics of poor prognosis, high morbidity and mortality worldwide. In particular, only a few systemic treatment options are available for advanced HCC patients, and include sorafenib and the recently described atezolizumab plus bevacizumab regimen as possible first-line treatments. We here propose acteoside, a phenylethanoid glycoside widely distributed in many medicinal plants as a potential candidate against advanced HCC. Methods Cell proliferation, colony formation and migration were analyzed in the three human HCC cell lines BEL7404, HLF and JHH-7. Angiogenesis assay was performed using HUVESs. The BEL7404 or JHH-7 xenograft nude mice model was established to analyze the possible antitumor effects of acteoside. qRT-PCR and western blotting were used to reveal the potential antitumor mechanisms of acteoside. Results Acteoside inhibited cell proliferation, colony formation and migration in all the three human HCC cell lines BEL7404, HLF and JHH-7. The prohibition of angiogenesis by acteoside was revealed by the inhibition of tube formation and cell migration of HUVECs. The combination of acteoside and sorafenib produced stronger inhibition of cell colony formation and migration of the HCC cells as well as of angiogenesis of HUVECs. The in vivo antitumor efficacy of acteoside was further demonstrated in BEL7404 or JHH-7 xenograft nude mice model, with an enhancement when combined with sorafenib in inhibiting the growth of JHH-7 xenograft. Further treatment of JHH-7 cells with acteoside revealed an increase in the level of tumor suppressor protein p53 as well as a decrease of kallikrein-related peptidase (KLK1, 2, 4, 9 and 10) gene level with no significant changes of the rest of KLK1–15 genes. Conclusions Acteoside exerts an antitumor effect possibly through its up-regulation of p53 levels as well as inhibition of KLK expression and angiogenesis. Acteoside could be useful as an adjunct in the treatment of advanced HCC in the clinic.

show abstract

Synergistic anticancer effect of acteoside and temozolomide-based glioblastoma chemotherapy

Cited by 11 publications

References 38 publications

Acteoside inhibits inflammatory response via JAK/STAT signaling pathway in osteoarthritic rats

Acteoside inhibits inflammatory response via JAK/STAT signaling pathway in osteoarthritic rats

Verbascoside—A Review of Its Antitumor Activities

Acteoside as a potential therapeutic option for primary hepatocellular carcinoma: a preclinical study

Contact Info

Product

Resources

About